Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Aug 8:11:182.
doi: 10.1186/1477-7819-11-182.

Systematic review and meta-analysis of laparoscopic and open gastrectomy for advanced gastric cancer

Ke Chen  1 , Xiao-Wu Xu, Yi-Ping Mou, Yu Pan, Yu-Cheng Zhou, Ren-Chao Zhang, Di Wu
Affiliations
Meta-Analysis

Systematic review and meta-analysis of laparoscopic and open gastrectomy for advanced gastric cancer

Ke Chen et al. World J Surg Oncol. .

Abstract

Background: The use of laparoscopic gastrectomy (LG) in advanced gastric cancer (AGC) remains a controversial topic, mainly because of doubts about its oncologic validity. This study is a systematic review and meta-analysis of the available evidence.

Methods: A comprehensive search was performed until June 2013 to identify comparative studies evaluating survival rates, recurrence rates, surgical outcomes and complications. Pooled risk ratios (RR) and weighted mean differences (WMD) with 95% confidence intervals (CI) were calculated using the random effects model. Data synthesis and statistical analysis were carried out using RevMan 5.1 software.

Results: Fifteen trials were involved in this analysis. Compared to open gastrectomy (OG), LG involved a longer operating time (WMD = 48.67 min, 95% CI 34.09 to 63.26, P < 0.001); less blood loss (WMD = -139.01 ml, 95% CI -174.57 to -103.44, P < 0.001); earlier time to flatus (WMD = -0.79 days, 95% CI -1.14 to -0.44, P < 0.001); shorter hospital stay (WMD = -3.11 days, 95% CI -4.13 to -2.09, P < 0.001); and a decrease in complications (RR = 0.74, 95% CI 0.61 to 0.90, P = 0.003). There was no significant difference in the number of harvested lymph nodes, margin distance, mortality, cancer recurrence rate and long-term survival rate between the AGC patients treated with LG or OG (P > 0.05).

Conclusions: Despite a longer operation, LG is a safe technical alternative to OG for AGC with a lower complication rate and enhanced postoperative recovery. Moreover, there were similar outcomes between both approaches in terms of cancer recurrence and the long-term survival rate. Because of the limitation of this study, methodologically high-quality studies are needed for further evaluation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of literature search strategies.
Figure 2
Figure 2
Meta-analysis of the pooled data: number of retrieved lymph nodes.
Figure 3
Figure 3
Meta-analysis of the pooled data: overall postoperative complications.
Figure 4
Figure 4
Funnel plot of the overall postoperative complications.
Figure 5
Figure 5
Meta-analysis of the pooled data: recurrences.
Figure 6
Figure 6
Meta-analysis of the pooled data: survival rate. (A) 3y-DFS, (B) 5y-DFS, (C) 1y-OS, (D) 3y-OS and (E) 5y-OS. DFS, disease-free survival; OS, overall survival; y, year.
See this image and copyright information in PMC

References

    1. Yako-Suketomo H, Katanoda K. Comparison of time trends in stomach cancer mortality (1990–2006) in the world, from the WHO mortality database. Jpn J Clin Oncol. 2009;11:622–623. doi: 10.1093/jjco/hyp107. - DOI - PubMed
    1. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M, La Vecchia C. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;11:666–673. doi: 10.1002/ijc.24290. - DOI - PubMed
    1. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;11:1810–1820. doi: 10.1056/NEJMoa072252. - DOI - PubMed
    1. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH. CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;11:315–321. doi: 10.1016/S0140-6736(11)61873-4. - DOI - PubMed
    1. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2009;11:127–164. doi: 10.1016/j.critrevonc.2009.01.004. - DOI - PubMed

LinkOut - more resources